Table 1 ECCQI respondent characteristics
HUN (n = 57) | PRT (n = 35) | NLD (n = 414) | ROM (n = 46) | LIT (n = 29) | ITA (n = 49) | FIN (n = 693) | CZE (n = 118) | Total (n = 1441) | |
|---|---|---|---|---|---|---|---|---|---|
Age | |||||||||
18–34 | – | – | 1.0 (4) | 4.3 (2) | 6.9% (2) | 4.1% (2) | 1.4% (10) | 5.1% (6) | 1.8% (26) |
35–64 | 68.4% (39) | 60.0% (21) | 42.3% (175) | 84.8% (39) | 72.4% (21) | 81.6% (40) | 63.3% (439) | 73.7% (87) | 59.8% (861) |
≥ 65 | 31.6% (18) | 40.0% (14) | 56.8% (235) | 10.9% (5) | 20.7% (6) | 14.3% (7) | 35.2% (244) | 21.2% (25) | 38.4% (554) |
Tumour type | |||||||||
Prostate | 12.3% (7) | 22.9% (8) | 63.3% (262) | 15.2% (7) | 44.8% (13) | 8.2% (4) | – | 39.8% (47) | 24.1% (348) |
Breast | 87.7% (50) | 77.1% (27) | 36.7% (152) | 84.8% (39) | 55.2% (16) | 91.8% (45) | 100% (693) | 60.2% (71) | 75.9% (1094 |
Education | |||||||||
Low | 7.0% (4) | 71.4% (25) | 3.6% (15) | 10.9% (5) | 13.8% (4) | 24.5% (12) | 1.4% (10) | 5.9% (7) | 5.7% (82) |
Moderate | 43.9% (25) | 17.1% (6) | 33.8% (140) | 37.0% (17) | 31.0% (9) | 46.9% (23) | 63.3% (439) | 34.7% (41) | 48.6% (700) |
High | 49.1% (28) | 11.4% (4) | 62.6% (259) | 52.2% (24) | 55.2% (16) | 28.6% (14) | 35.2% (244) | 59.3% (70) | 45.7% (659) |
Physical health | |||||||||
Excellent | 8.8% (5) | – | 4.9% (20) | – | 3.4% (1) | 8.2% (4) | 4.2% (29) | 3.4% (4) | 4.4% (63) |
Very good | 17.5% (10) | – | 20.9% (85) | 20.0% (9) | 10.3% (3) | 16.3% (8) | 26.2% (181) | 35.9% (42) | 23.6% (338) |
Good | 28.1% (16) | 34.0% (12) | 58.7% (239) | 51.1% (23) | 55.2% (16) | 42.9% (21) | 48.1% (333) | 46.2% (54) | 49.9% (714) |
Moderate | 40.4% (23) | 51.4% (18) | 14.7% (60) | 26.7% (12) | 27.6% (8) | 28.6% (14) | 16.5% (114) | 12.0% (14) | 18.3% (262) |
Poor | 5.3% (3) | 14.3% (5) | 0.7% (3) | 2.2% (1) | 3.4% (1) | 4.1% (2) | 5.1% (35) | 2.6% (3) | 3.7% (53) |
Treatment stage | |||||||||
Test to ascertain diagnosis | 1.8% (1) | – | 5.1% (21) | 2.2% (1) | 17.2% (5) | – | 0.9% (6) | 0.8% (1) | 2.4% (35) |
Diagnosis known, will be treated soon | 5.5% (3) | 5.7% (2) | 1.2% (5) | 2.2% (1) | 17.2% (5) | 6.3% (3) | 0.1% (1) | – | 1.4% (20) |
Curative treatment | 32.7% (18) | 57.1% (20) | 16.3% (67) | 65.2% (30) | 44.8% (13) | 70.8% (34) | 24.8% (171) | 21.2% (25) | 26.4% (377) |
No further treatment possible | – | – | 0.5% (2) | 2.2% (1) | – | – | 0.1% (1) | – | 0.3% (4) |
Non-curative treatment | 5.5% (3) | 28.6% (10) | 7.8% (32) | 8.7% (4) | – | 2.1% (1) | 7.0% (48) | 9.3% (11) | 7.6% (109) |
Check-up or treatments of the symptoms | 43.6% (24) | 8.6% (3) - | 61.5% (252) | 17.4% (8) | 20.7% (6) | 18.8% (9) | 65.9% (455) | 65.3% (77) | 58.3% (834) |
Finished check-ups and treatment | 10.9% (6) | 6.3% (26) | 2.2% (1) | – | 2.1% (1) | 0.7% (5) | 2.5% (3) | 2.9% (42) | |
Patient does no longer remember | – | – | 1.2% (5) | – | – | – | 0.4% (3) | 0.8% (1) | 0.6% (9) |
Time since last hospital visit | |||||||||
< 1 month | 54.4% (31) | 91.4% (32) | 38.5% (159) | 73.9% (34) | 50.0% (14) | 83.7% (41) | 28.8% (199) | 42.4% (50) | 38.9% (559) |
1–2 months | 17.5% (10) | 2.9% (1) | 24.0% (99) | 6.5% (3) | 14.3% (4) | 6.1% (3) | 8.8% (61) | 40.7% (48) | 15.9% (229) |
2–4 months | 10.5% (6) | 2.9% (1) | 22.3% (92) | 13.0% (6) | 21.4% (6) | – | 16.5% (114) | 12.7% (15) | 16.7% (240) |
4–8 months | 5.3% (3) | – | 9.2% (38) | 4.3% (2) | 3.6% (1) | 4.1% (2) | 20.8% (144) | 3.4% (4) | 13.5% (194) |
8–12 months | 7.0% (4) | 2.9% (1) | 3.6% (15) | 2.2% (1) | 7.1% (2) | 4.1% (2) | 19.2% (133) | – | 11.0% (158) |
> 12 months | 5.3% (3) | – | 2.4% (10) | – | 3.6% (1) | 2.0% (1) | 5.8% (40) | 0.8% (1) | 3.9% (56) |